ORBIMED ADVISORS LLC - 23 Oct 2025 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Reporting relationship: 10%+ Owner
Issuer ticker: PMVP
Reported as of: 23 Oct 2025
Net transaction value: -$1,520,000
SEC form: 4
Accepted by SEC: 27 Oct 2025, 17:19:23 UTC
Prior SEC filing: 10 Oct 2025
Next SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for PMV Pharmaceuticals, Inc. (PMVP) on 27 Oct 2025.

Key facts

This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for PMV Pharmaceuticals, Inc. (PMVP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Oct 2025, 17:19.

Change

Previous filing in this sequence was filed on 10 Oct 2025.
Current net transaction value: -$1,520,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001055951 Primary reporting owner

ORBIMED ADVISORS LLC

Relationship: 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Signature date: 27 Oct 2025

CIK 0001615374

OrbiMed Capital GP V LLC

Relationship: 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of the Managing Member of OrbiMed Capital GP V LLC
Signature date: 27 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PMVP transaction

Common Stock

Sale

Transaction value: $1,520,000
Shares: -1,000,000
Change %: -17%
Price: $1.52
Shares after: 4,975,291
Date: 23 Oct 2025
Ownership: See Footnotes
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.

Footnote F2

This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.